Compare AbCellera Biologics Inc (ABCL) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Hyatt Hotels Corporation — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Hyatt Hotels Corporation trades at $187.9 (market cap $18.19B). The key difference: Hyatt Hotels Corporation is far larger — about 7.7× AbCellera Biologics Inc's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | H | |
|---|---|---|
Market Cap | $2.35B | $18.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $202.09 |
52-Week Low | $2.78 | $135.01 |
Enterprise Value | $1.99B | $22.03B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Hyatt Hotels (H) trades at $193.16, up 0.98% with a neutral technical signal. The stock shows mixed fundamentals with negative net income margins (-0.48%) and ROE (-1.02%) despite revenue growth to $7.1B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus targets $197.30. The company continues expansion with new hotel announcements and maintains strong institutional support.
Investment outlook is cautiously optimistic given analyst buy ratings (37.5%) and expansion initiatives, but risks include declining cash flow trends and elevated debt levels. The stock faces pressure from negative profitability metrics despite revenue stability, requiring careful monitoring of upcoming Q2 2026 earnings against the $0.89 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
